Jee Bang, MD
Internal Medicine · Worcester, MANPI 1225265937
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,421 of the $15,600 with a category attached, or 66.8%. 8 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 46.7% of the total. Reporting peaked in 2024 at $10,144 and has fallen 97.6% since, to $248 in 2025. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $537.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$7K
- F. Hoffmann-la Roche AG$3K
- Roche Products Limited$3K
- Sage Therapeutics, LLC$1K
- Vertex$242
- PTC Therapeutics, Inc.$233
- plus $106 from 2 others
Across 134 payments — averaging $21,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.9M
- Sage Therapeutics, LLC$436K
- F. Hoffmann-la Roche AG$118K
- Biogen$116K
- Novartis$61K
- Biohaven Pharmaceuticals, Inc.$51K
- plus $118K from 4 others
What the payments were for
- Consulting fees$2,16214%
- Speaking & faculty fees$1,56510%
- Travel & lodging$10,42167%
- Food & beverage$1,4389%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 8 | $7,286 |
| F. Hoffmann-la Roche AG | 3 | $3,485 |
| Roche Products Limited | 5 | $3,043 |
| Sage Therapeutics, LLC | 9 | $1,206 |
| Vertex | 1 | $242 |
| PTC Therapeutics, Inc. | 1 | $233 |
| Genentech USA, Inc. | 1 | $91 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$3,485
How this compares
$15,600 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 43 | $347,476 |
| Austedo XrDeutetrabenazine | 22 | $86,186 |
| Tetrabenazine | 18 | $75,993 |
| GocovriAmantadine Hcl | 12 | $41,106 |
| Risperidone | 111 | $944 |
| RivastigmineRivastigmine Tartrate | 12 | $589 |
| Escitalopram Oxalate | 18 | $435 |
| Donepezil Hcl | 38 | $425 |
| Sertraline Hcl | 18 | $177 |
| Trazodone Hcl | 14 | $89 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Worcester
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.